scholarly journals A first‐in‐human oral dose study of mesdopetam (IRL790) to assess its safety, tolerability, and pharmacokinetics in healthy male volunteers

2021 ◽  
Vol 9 (3) ◽  
Author(s):  
Folke Sjöberg ◽  
Susanna Waters ◽  
Boel Löfberg ◽  
Clas Sonesson ◽  
Nicholas Waters ◽  
...  
Keyword(s):  
Oral Dose ◽  
Healthy Male ◽  
Healthy Male Volunteers ◽  
Male Volunteers ◽  
Dose Study

scholarly journals A first-in-human oral dose study of mesdopetam (IRL790) to assess its safety, tolerability, and pharmacokinetics in healthy male volunteers.

2020 ◽  
Author(s):  
Folke Sjoberg ◽  
Susanna Waters ◽  
Boel L fberg ◽  
Claes Sonesson ◽  
Nicholas Waters ◽  
...  
Keyword(s):  
Oral Dose ◽  
Healthy Male ◽  
Healthy Male Volunteers ◽  
Male Volunteers ◽  
Dose Study

scholarly journals Usefulness of serotoninergic challenge with oral citalopram

2006 ◽  
Vol 28 (3) ◽  
pp. 203-205 ◽  
Author(s):  
Paulo Mattos ◽  
Vanessa A Franco ◽  
François Noel ◽  
Daniel Segenreich ◽  
José Carlos Gonçalves
Keyword(s):  
Growth Hormone ◽  
Oral Dose ◽  
Intravenous Administration ◽  
Small Amplitude ◽  
Challenge Test ◽  
Healthy Male ◽  
Healthy Male Volunteers ◽  
Male Volunteers ◽  
Challenge Tests ◽  
Higher Doses

OBJECTIVE: Challenge tests designed to evaluate serotoninergic pathways have widely used intravenous citalopram. Oral citalopram has also been used, but unsatisfactory results were obtained with a dose of 20 mg. The objective of this study was to determine whether a higher oral dose would reproduce similar to those described for intravenous administration. To that end, we evaluated cortisol, growth hormone and prolactin levels. METHOD: Eight healthy male volunteers were evaluated in a randomized crossover challenge test with 40 mg of oral citalopram or placebo. RESULTS: Cortisol levels increased at 2-4h after the oral citalopram intake, with a small amplitude peak occurring in two-thirds of the subjects. Levels of prolactin and growth hormone remained unchanged throughout the study. CONCLUSION: The use of oral citalopram might present an alternative in serotoninergic challenge tests, but higher doses are required.

A phase I study to determine the effect of tamoxifen on the pharmacokinetics of a single 250 mg oral dose of gefitinib (IRESSA) in healthy male volunteers

2005 ◽  
Vol 56 (6) ◽  
pp. 557-562 ◽  
Author(s):  
Mireille V. Cantarini ◽  
Merran P. Macpherson ◽  
Anna L. Marshall ◽  
Anna V. Robinson ◽  
Christopher J. Bailey
Keyword(s):  
Oral Dose ◽  
Phase I ◽  
Phase I Study ◽  
Healthy Male ◽  
Healthy Male Volunteers ◽  
Male Volunteers
Sign in / Sign up

Export Citation Format

Share Document